Deutsche Bank Takes Cautious Stance on Siemens Healthineers Outlook

Deutsche Bank slashes Siemens Healthineers price target to €42, citing weak Q2 outlook and headwinds in diagnostics and margins. Shares trade near 52-week low.

In a recent research note, Deutsche Bank has adopted a notably more conservative view on Siemens Healthineers. The bank's analyst, Falko Friedrichs, revised his price target downward on March 27, cutting it from €46 to €42 per share. This adjustment solidifies the bank's position among the more pessimistic market voices regarding the medical technology firm's near-term prospects.

A Significant Deviation from the Consensus

Deutsche Bank's new €42 target places it firmly at the lower end of market expectations. This stands in stark contrast to the broader analyst consensus, which sits at €55.02. Currently, twenty market experts tracking the stock maintain an average "buy" recommendation, with the most bullish price target on the street reaching €63.

The shares recently touched a fresh 52-week low of €35.66, trading approximately 20% below their 200-day moving average. Despite the reduced target, Deutsche Bank's forecast still implies a potential upside of roughly 18% from current levels. The firm has maintained its "Hold" rating on the equity.

Underlying Concerns for the Current Quarter

The rationale for the downgrade centers on expectations for a challenging second fiscal quarter. Friedrichs projects organic revenue growth of just 3% for the period. His forecast for key earnings metrics is even more subdued, anticipating a decline of approximately 16% compared to the same quarter last year.

Several headwinds are cited as drivers of this pressured outlook. The analysis points to softness in the diagnostics business unit, adverse currency exchange effects, and tariff impacts that are compressing margins. Furthermore, geopolitical tensions introduce additional risk. The ongoing conflict in the Middle East is identified as a potential threat to the company's ability to achieve its full-year objectives. While the bank assesses that corporate parent Siemens AG would see only a marginal impact from investment delays in Iran, the medical technology division is viewed as more sensitive to regional instability.

The company's upcoming Q2 report will serve as a critical test. Meeting these already-diminished expectations is seen as a necessary first step for any potential stabilization in the share price.